Capricor Therapeutics’ (CAPR) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report report published on Friday, Benzinga reports. Cantor Fitzgerald currently has a $8.00 price objective on the biotechnology company’s stock.

A number of other research firms have also recently weighed in on CAPR. HC Wainwright reissued a buy rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research note on Tuesday. Maxim Group reiterated a buy rating and issued a $12.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday. Finally, Oppenheimer raised their target price on Capricor Therapeutics from $14.00 to $15.00 and gave the stock an outperform rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus target price of $20.00.

Capricor Therapeutics Trading Up 1.2 %

Shares of CAPR stock opened at $5.05 on Friday. Capricor Therapeutics has a 12 month low of $2.68 and a 12 month high of $7.28. The company has a market capitalization of $161.49 million, a P/E ratio of -5.80 and a beta of 3.92. The stock has a 50 day moving average of $4.37 and a two-hundred day moving average of $5.18.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The firm had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Sell-side analysts predict that Capricor Therapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CAPR. Marshall Wace LLP bought a new position in Capricor Therapeutics in the 2nd quarter valued at $426,000. Renaissance Technologies LLC lifted its position in Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after buying an additional 84,350 shares in the last quarter. Main Street Financial Solutions LLC grew its holdings in Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares during the last quarter. Rhumbline Advisers bought a new stake in Capricor Therapeutics during the 2nd quarter worth about $147,000. Finally, Bank of New York Mellon Corp increased its position in Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 9,040 shares in the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.